Jeffrey Nau - Oct 21, 2021 Form 4 Insider Report for Oyster Point Pharma, Inc. (OYST)

Role: President and CEO, Director
Signature: /s/ Brandon Fenn, Attorney-in-Fact
Stock symbol: OYST
Transactions as of: Oct 21, 2021
Transactions value $: $51,000
Form type: 4
Date filed: 10/22/2021, 04:41 PM
Previous filing: Sep 1, 2021
Next filing: Jan 11, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OYST	Common Stock	Options Exercise	$51K	+50K	+82.1%	$1.02^*	111K	Oct 21, 2021	Direct
holding	OYST	Common Stock						1K	Oct 21, 2021	See Footnote	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OYST	Employee Stock Option (Right to Buy)	Options Exercise	$0	-50K	-10.31%	$0.00	435K	Oct 21, 2021	Common Stock	50K	$1.02	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are held by the Reporting Person's spouse.
F2	This option was granted on November 10, 2017 under the Oyster Point Pharma, Inc. 2016 Equity Incentive Plan. One forty-eighth of the total number of shares subject to the original option vested on December 1, 2017, and one forty-eighth of the remaining shares vested, and continue to vest, monthly thereafter, subject to continued service to the Issuer through each such vesting date. The award is subject to vesting acceleration under certain circumstances.

Content

These shares are held by the Reporting Person's spouse.

This option was granted on November 10, 2017 under the Oyster Point Pharma, Inc. 2016 Equity Incentive Plan. One forty-eighth of the total number of shares subject to the original option vested on December 1, 2017, and one forty-eighth of the remaining shares vested, and continue to vest, monthly thereafter, subject to continued service to the Issuer through each such vesting date. The award is subject to vesting acceleration under certain circumstances.